Bennett Levitan

2.0k citations

80 papers · 1.3k · h-index 20

Impact in

Internal Medicine top 5%
- Venous Thromboembolism Diagnosis and Management
Economics and Econometrics top 2%
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Environmental Valuation
- Pharmaceutical Economics and Policy

Papers in

Economics and Econometrics 38
- Health Systems, Economic Evaluations, Quality of Life 34
- Pharmaceutical Economics and Policy 10
- Economic and Environmental Valuation 7
Cardiology and Cardiovascular Medicine 18
- Atrial Fibrillation Management and Outcomes 16

Co-authors: Esther W. de Bekker‐Grob (11 shared papers)Juhaeri Juhaeri (9 shared papers)Chiara Whichello (9 shared papers)Jorien Veldwijk (9 shared papers)Isabelle Huys (8 shared papers)Žhong Yuan (18 shared papers)Eline van Overbeeke (7 shared papers)Brett Hauber (12 shared papers)
Journals: Value in Health (11 papers)Therapeutic Innovation & Regulatory Science (6 papers)Patient (5 papers)Frontiers in Pharmacology (3 papers)Vaccine (2 papers)
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Bennett Levitan

79 papers receiving 1.2k citations

Peers

Countries citing papers authored by Bennett Levitan

Since Specialization

Citations

This map shows the geographic impact of Bennett Levitan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bennett Levitan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bennett Levitan more than expected).

Fields of papers citing papers by Bennett Levitan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bennett Levitan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bennett Levitan. The network helps show where Bennett Levitan may publish in the future.

Co-authors

The 25 scholars most cited alongside Bennett Levitan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bennett Levitan Line = papers co-authored together Bennett Levitan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 80 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review Drug Discovery Today ·Vikas Soekhai, Chiara Whichello, Bennett Levitan, Jorien Veldwijk, Cathy Anne Pinto, Bas Donkers, Isabelle Huys, Eline van Overbeeke, Juhaeri Juhaeri, Esther W. de Bekker‐Grob	2019	103
2	A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies Value in Health ·Martin Ho, Anindita Saha, Kimberly McCleary, Bennett Levitan, Stephanie Christopher, Kristen Zandlo, R. Scott Braithwaite, Brett Hauber	2016	100
3	Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI’s Patient Groups and Clinical Trials Project Therapeutic Innovation & Regulatory Science ·Bennett Levitan, Kenneth Getz, Eric L. Eisenstein, Michelle P. Goldberg, Matthew Harker, Sharon Hesterlee, Bray Patrick‐Lake, Jamie Roberts, Joseph A. DiMasi	2017	94
4	Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review Drug Discovery Today ·Eline van Overbeeke, Chiara Whichello, Rosanne Janssens, Jorien Veldwijk, Irina Cleemput, Steven Simoens, Juhaeri Juhaeri, Bennett Levitan, Jürgen Kübler, Esther W. de Bekker‐Grob, Isabelle Huys	2018	72
5	Stochastic modeling and optimization of phage display 1 1Edited by J. A. Wells Journal of Molecular Biology ·Bennett Levitan	1998	57
6	Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study Frontiers in Pharmacology ·Eline van Overbeeke, Rosanne Janssens, Chiara Whichello, Karin Schölin Bywall, Jenny Sharpe, Nikoletta Nikolenko, Berkeley Phillips, Paolo Guiddi, Gabriella Pravettoni, Laura Vergani, Giulia Marton, Irina Cleemput, Steven Simoens, Jürgen Kübler, Juhaeri Juhaeri, Bennett Levitan, Esther W. de Bekker‐Grob, Jorien Veldwijk, Isabelle Huys	2019	55
7	Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study Clinical and Applied Thrombosis/Hemostasis ·Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Žhong Yuan, Bennett Levitan, Chiara Sugarmann, Yoriko De Sanctis, Theodore E. Spiro, Elliot S. Barnathan, Gary E. Raskob	2019	46
8	Adaptive walks with noisy fitness measurements Molecular Diversity ·Bennett Levitan, Stuart Kauffman	1995	41
9	Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review BMC Medical Informatics and Decision Making ·Rosanne Janssens, Isabelle Huys, Eline van Overbeeke, Chiara Whichello, Sarah Harding, Jürgen Kübler, Juhaeri Juhaeri, Antonio Ciaglia, Steven Simoens, Hilde Stevens, Meredith Y. Smith, Bennett Levitan, Irina Cleemput, Esther W. de Bekker‐Grob, Jorien Veldwijk	2019	37
10	Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions Clinical Pharmacology & Therapeutics ·Francesco Pignatti, Deborah Ashby, EP Brass, H‐G Eichler, Pascal Frey, HL Hillege, Akiko Hori, Bennett Levitan, Lawrence Liberti, RE Löfstedt, Neil McAuslane, Alain Micaleff, R A Noel, Douwe Postmus, Ortwin Renn, BJ Sabourin, Tomas Salmonson, Stuart Walker	2015	34
11	Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison BMC Medical Informatics and Decision Making ·Chiara Whichello, Bennett Levitan, Juhaeri Juhaeri, Vaishali Patadia, Rachael L. DiSantostefano, Cathy Anne Pinto, Esther W. de Bekker‐Grob	2020	33
12	Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty Vascular Health and Risk Management ·Bennett Levitan, Žhong Yuan, Alexander G.G. Turpie, Richard J. Friedman, Martin Homering, Jesse A. Berlin, Scott D. Berkowitz, Rachel Weinstein, Peter M. DiBattiste	2014	28
13	Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies Annals of General Psychiatry ·Michael A. Markowitz, Dong‐Jing Fu, Bennett Levitan, Srihari Gopal, Ibrahim Turkoz, Larry Alphs	2013	28
14	Patient Engagement at a Tipping Point—The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, “Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products” Therapeutic Innovation & Regulatory Science ·Meredith Y. Smith, Tarek A. Hammad, Marilyn Metcalf, Bennett Levitan, Rebecca Noel, Anne M. Wolka, Debra L. Michaels, F. Reed Johnson	2016	26
15	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE CHEST Journal ·Philip S. Wells, Martin H. Prins, Bennett Levitan, Jan Beyer‐Westendorf, Timothy Brighton, Henri Bounameaux, Alexander T. Cohen, Bruce L. Davidson, Paolo Prandoni, Gary E. Raskob, Žhong Yuan, Eva G. Katz, Martin Gebel, Anthonie W.A. Lensing	2016	26
16	Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives Current Medical Research and Opinion ·Žhong Yuan, Bennett Levitan, Paul Burton, Christine Poulos, Brett Hauber, Jesse A. Berlin	2014	25
17	Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression Clinical Pharmacology & Therapeutics ·Eva G. Katz, David Hough, Teodora Doherty, Rosanne Lane, Jaskaran Singh, Bennett Levitan	2020	24
18	Patients’ Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment Psychiatric Services ·Bennett Levitan, Michael A. Markowitz, Ateesha F. Mohamed, F. Reed Johnson, Larry Alphs, Leslie Citrome, John F. P. Bridges	2015	24
19	Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials Patient Preference and Adherence ·Eva G. Katz, Brett Hauber, Srihari Gopal, Angie Fairchild, Amy Pugh, Rachel Weinstein, Bennett Levitan	2016	21
20	Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US Frontiers in Pharmacology ·Chiara Whichello, Eline van Overbeeke, Rosanne Janssens, Karin Schölin Bywall, Selena Russo, Jorien Veldwijk, Irina Cleemput, Juhaeri Juhaeri, Bennett Levitan, Jürgen Kübler, Meredith Y. Smith, Richard Hermann, Matthias Englbrecht, Axel J. Hueber, Alina Comanescu, Sarah Harding, Steven Simoens, Isabelle Huys, Esther W. de Bekker‐Grob	2019	19

About Bennett Levitan

Bennett Levitan is a scholar working on Economics and Econometrics, Cardiology and Cardiovascular Medicine, Pharmacology, Internal Medicine and General Health Professions, having authored 80 papers that have together received 1.3k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (34 papers), Pharmaceutical industry and healthcare (18 papers), Atrial Fibrillation Management and Outcomes (16 papers), Venous Thromboembolism Diagnosis and Management (13 papers), Pharmaceutical Economics and Policy (10 papers), Economic and Environmental Valuation (7 papers), Patient-Provider Communication in Healthcare (7 papers) and Pharmaceutical studies and practices (6 papers). The work is most often cited by research in Internal Medicine (152 citations), Economics and Econometrics (530 citations), General Decision Sciences (32 citations), Pharmacology (119 citations) and Toxicology (43 citations). Bennett Levitan has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Esther W. de Bekker‐Grob, Juhaeri Juhaeri, Chiara Whichello, Jorien Veldwijk, Isabelle Huys, Žhong Yuan, Eline van Overbeeke, Brett Hauber, Stuart Kauffman and Cathy Anne Pinto. Their work appears in journals such as Value in Health, Therapeutic Innovation & Regulatory Science, Patient, Frontiers in Pharmacology and Vaccine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Bennett Levitan

Impact in

Papers in i

In The Last Decade

Bennett Levitan

Peers

Countries citing papers authored by Bennett Levitan

Fields of papers citing papers by Bennett Levitan

All Works

About Bennett Levitan

Explore authors with similar magnitude of impact

Papers in